MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2013-08-30
Last Posted Date
2013-08-30
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
36
Registration Number
NCT01932333

Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2013-06-13
Last Posted Date
2013-06-13
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
18
Registration Number
NCT01877226

An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury

Phase 2
Terminated
Conditions
Traumatic Brain Injury
Interventions
First Posted Date
2013-03-20
Last Posted Date
2013-05-01
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
7
Registration Number
NCT01814982

A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Other: Placebo
First Posted Date
2013-03-18
Last Posted Date
2014-03-18
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
33
Registration Number
NCT01812642

A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)
First Posted Date
2013-02-13
Last Posted Date
2016-06-29
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
6
Registration Number
NCT01791231

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2013-02-08
Last Posted Date
2016-06-29
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
60
Registration Number
NCT01787357

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

Phase 1
Completed
Conditions
Renal Insufficiency
Healthy
Interventions
First Posted Date
2013-01-03
Last Posted Date
2013-05-29
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
40
Registration Number
NCT01759576
© Copyright 2025. All Rights Reserved by MedPath